CoChat

Personalized management of dyslipidemias in patients with diabetes—it is time for a new approach (2022)

Open access
Banach, Maciej, Surma, Stanisław, Reiner, Zeljko, Katsiki, Niki, Penson, Peter E., Fras, Zlatko, Sahebkar, Amirhossein, Paneni, Francesco, Rizzo, Manfredi, Kastelein, John · 2022 · Cardiovascular Diabetology
Cited by 100

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

Dyslipidemia in patients with type 2 diabetes (DMT2) is one of the worst controlled worldwide, with only about 1/4 of patients being on the low-density lipoprotein cholesterol (LDL-C) target. There are many reasons of this, including physicians’ inertia, including diabetologists and cardiologists, therapy nonadherence, but also underusage and underdosing of lipid lowering drugs due to unsuitable cardiovascular (CV) risk stratification. In the last several years there is a big debate on the risk stratification of DMT2 patients, with the strong indications that all patients with diabetes should be at least at high cardiovascular disease (CVD) risk. Moreover, we have finally lipid lowering drugs, that not only allow for the effective reduction of LDL-C and do not increase the risk of new onset diabetes (NOD), and/or glucose impairment; in the opposite, some of them might effectively improve glucose control. One of the most interesting is pitavastatin, which is now available in Europe, with the best metabolic profile within statins (no risk of NOD, improvement of fasting blood glucose, HOMA-IR, HbA1c), bempedoic acid (with the potential for the reduction of NOD risk), innovative therapies—PCSK9 inhibitors and inclisiran with no DMT2 risk increase, and new forthcoming therapies, including apabetalone and obicetrapib—for the latter one with the possibility of even decreasing the number of patients diagnosed with prediabetes and DMT2. Altogether, nowadays we have possibility to individualize lipid lowering therapy in DMT2 patients and increase the number of patients on LDL-C goal without any risk of new onset diabetes and/or diabetes control worsening, and in consequence to reduce the risk of CVD complications due to progression of atherosclerosis in this patients’ group.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12933-022-01684-5

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Cited by

See all 100

Metadata

Authors
Banach, M., Surma, S., Reiner, Z., Katsiki, N., Penson, P. E., Fras, Z., Sahebkar, A., Paneni, F., Rizzo, M., & Kastelein, J.
Venue
Cardiovascular Diabetology
Published
2022-11-28
Volume
21
Issue
1
Pages
263-263
ISSN
1475-2840 (ISSN-L)
OpenAlex
W4310117874
Cited by
100
References
16
FWCI
18.44
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Personalized management of dyslipidemias in patients with diabetes—it is time for a new approach (2022). https://app.cochat.ai/papers/10.1186/s12933-022-01684-5
The paper
Banach, M., Surma, S., Reiner, Z., Katsiki, N., Penson, P. E., Fras, Z., Sahebkar, A., Paneni, F., Rizzo, M., & Kastelein, J. (2022). Personalized management of dyslipidemias in patients with diabetes—it is time for a new approach (2022). Cardiovascular Diabetology. https://doi.org/10.1186/s12933-022-01684-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.